NCT05572944 Formatting the Risk Prediction Models for Never-Smoking Lung Cancer
| NCT ID | NCT05572944 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chung Shan Medical University |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2022-12-15 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2022-12-15 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung Cancer is the leading cause of cancer-related deaths in Taiwan and worldwide and the incidence is also increasing. The payment for lung cancer which occupies the largest part of National Health Insurance expense is over 15 billion in 2018. Because about 80% lung cancer patients are smokers in western countries the low-dose computed tomography screening focuses on the smoking population It is quite different in South-East Asia particularly in Taiwan that 53% of Taiwan lung cancer are never-smokers and the etiology and the underlying mechanisms are still unknown. The preliminary results of prospective TALENT study indicated that family history plays a key role in tumorigenesis of Taiwan lung cancers but several important variables such as air pollution, biomarkers, radiomics analysis are not available limits the accuracy of lung cancer identification. Hence, it is critical to integrate most of factors involved in lung cancer formation into a multidimensional lung cancer prediction model which could benefit never-smoker lung cancers in Taiwan and East Asia even in the western countries. The investigators initiate a clinical study to validate the multidimensional lung cancer prediction model for never-smoking population by multicenter prospective study.
Eligibility Criteria
Inclusion Criteria: 1. Age 50-80 years old 2. First-degree relatives of lung cancer patients * aged more than 50 - 80 years old * or older than the age at diagnosis of the youngest lung cancer the proband in the family if they are less than 50 years old Exclusion Criteria: 1. Previous history of lung cancer 2. Another malignancy except for cervical carcinoma in situ or non-melanomatous carcinoma of the skin within 5 years 3. An inability to tolerate transthoracic procedures or thoracotomy 4. Chest CT examination was performed within 18 months 5. Hemoptysis of unknown etiology within one month 6. Body weight loss of more than 6 kg within one year without an evident cause 7. A known pregnancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05572944 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 80 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05572944 currently recruiting?
Yes, NCT05572944 is actively recruiting participants. Contact the research team at geechen@gmail.com for enrollment information.
Where is the NCT05572944 trial being conducted?
This trial is being conducted at Taichung, Taiwan, Hsinchu, Taiwan, Hualien City, Taiwan, Kaohsiung City, Taiwan and 3 additional locations.
Who is sponsoring the NCT05572944 clinical trial?
NCT05572944 is sponsored by Chung Shan Medical University. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.